Medication info

Boryung Pregabalin Capsule 300 mg

Prescription medicationOralExpired
Ingredient · strength
Pregabalin›300mg / 1 capsule
Manufacturer / importer
Boryung Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a brown upper part and white lower part containing a white or light yellow powder.
Packaging
30 capsules per bottle, 100 capsules per bottle
Approval status
Expired

MFDS item code 202001271 · Approved 2020.02.21

This product's status changed to Expired on 2025.02.21. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, in 2 divided doses per day, with or without food. Since this medicine is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the following formula. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration method Initial dose (mg/day) Maximum dose (mg/day) ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the administration method. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
7. Pediatric and Adolescent Patients Administration is not recommended in children under 12 years of age or adolescent patients aged 12–17 years because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Boryung Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also administered as an adjunct for patients with epilepsy for partial seizures with or without secondary generalization. It helps alleviate symptoms in patients with fibromyalgia. In summary, this drug is effective for managing neuropathic pain, controlling epileptic seizures, and relieving fibromyalgia symptoms.

How to take

Adult dose

This medicine is administered orally as pregabalin, in 2 divided doses per day, with or without food. Since this medicine is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the following formula. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration method Initial dose (mg/day) Maximum dose (mg/day) ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the administration method. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

7. Pediatric and Adolescent Patients Administration is not recommended in children under 12 years of age or adolescent patients aged 12–17 years because there are insufficient safety and efficacy data.

Precautions

This drug affects the central nervous system, and there is a risk of suicidal thoughts, suicidal behavior, or depression symptoms during treatment; therefore, patients and caregivers should closely monitor for such changes. This drug should not be taken by patients with certain genetic disorders, especially those with lactose intolerance. Diabetic patients may need to adjust their blood sugar control medications due to weight gain after taking this drug; caution is advised. An allergic reaction such as angioedema may occur; if symptoms such as swelling of the face or around the mouth appear, treatment should be discontinued immediately. Elderly patients should exercise caution as the use of this drug may increase dizziness or drowsiness, raising the risk of falls or injuries. Some patients may experience blurred vision or changes in eyesight after taking this drug, and these symptoms may improve upon discontinuation of the medication. Discontinuation of this medication may cause withdrawal symptoms such as insomnia, headache, and anxiety; therefore, it should not be abruptly stopped and should follow a doctor's advice. There is a potential for drug abuse or dependence, so patients with a history of drug abuse should be closely monitored. Patients with impaired kidney function should have their dosage adjusted, and those with heart disease should also use caution. Caution is needed when taking this drug with opioid analgesics, as it can increase central nervous system depression, which risks respiratory depression. In early pregnancy, taking this drug may impact the fetus; therefore, pregnant women or those planning to become pregnant should consult their physician and use effective contraception. Women who are breastfeeding should consult their physician as this drug may be passed into breast milk and affect the infant. They may need to stop breastfeeding or discontinue the drug. Caution is advised when engaging in hazardous activities such as driving or operating machinery, as dizziness or drowsiness may occur after taking this drug. This drug should be kept out of reach of children, and transferring it to another container may pose risks of accidents and degradation of quality.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, swelling around the mouth, upper respiratory tract swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, loss of appetite, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, sexual dysesthesia, restlessness, anxiety, mood swings, emotional withdrawal, emotional elevation, hallucinations, abnormal dreams, increased libido, panic attacks, lack of impulse control, apathy, ataxia, abnormal motor coordination, balance disorders, amnesia, attention disorders, memory disorders, tremors, dysarthria, sensory disturbances, sensory loss, sedation, drowsiness, cognitive impairment, nystagmus, speech disorders, muscular hypertonicity, diminished reflexes, abnormal movements, psychomotor agitation, position-related dizziness, sensory hypersensitivity, burning sensation, activity tremors, syncope, confusion, bradylalia, olfactory disturbances, loss of taste, writing difficulties, double vision, dry eyes, eye swelling, vision reduction, eye pain, eye fatigue, increased tear production, eye irritation, mydriasis, changes in depth perception during vibration, strabismus, brightness in the visual field, vertigo, auditory hypersensitivity, first-degree heart block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral cyanosis, dyspnea, epistaxis, coughing, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal bloating, constipation, dry mouth, distension, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urinary disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, nipple discharge, breast enlargement, peripheral edema, swelling, gait abnormalities, falls, feeling of intoxication, altered sensation, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood glucose, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reaction, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), emotional disturbance, drowsiness, state of confusion, agitation, restlessness, convulsions, shock, anaphylactic-like symptoms, skin and mucous membrane syndrome, erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This drug may be sensitive to air or moisture; it should be stored in a tightly sealed container. The storage temperature should be maintained at room temperature between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a brown upper part and white lower part containing a white or light yellow powder.

Package unit

30 capsules per bottle, 100 capsules per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.